Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

Early PET-Negative Stage I/II Hodgkin Lymphoma Patients Show Increased Risk of Early Relapse when Radiotherapy Is Not Used

By Medimaging International staff writers
Posted on 23 Apr 2014
Print article
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Analysis of a new study indicates an increased risk of early relapse when excluding radiotherapy in early positron emission tomography (PET) scan-negative patients with stage I/II Hodgkin’s lymphoma.

The interim analysis of the intergroup EORTC-LYSA-FIL 20051 H10 trial was published online March 17, 2014, in the Journal of Clinical Oncology. Early outcome, however, was excellent in both arms, and the final analysis should reveal whether these preliminary findings are upheld over time.

Dr. J.M.M. Raemaekers, from the Radboud University Medical Center (Nijmegen, The Netherlands), and central coordinator of the study stated, “The standard treatment for patients with clinical stage I/II Hodgkin’s lymphoma is ABVD [adriamycin, bleomycin, vinblastin and dacarbazin] chemotherapy followed by radiotherapy. Striking the right balance between initial cure through combined modality treatment and accepting a higher risk of late complications, and a higher recurrence rate after omitting radiotherapy in subsets of patients who will subsequently need intensive salvage treatment, is a matter of unsettled debate.”

The main objective of the H10 trial was to evaluate whether involved-node radiotherapy could be omitted without loss of efficacy in terms of progression-free survival in patients with stage I/II Hodgkin’s lymphoma who had a negative early PET scan after two cycles of ABVD chemotherapy. This interim trial analysis included a total of 1,137 patients with untreated clinical stage I/II Hodgkin’s lymphoma. Of these, 444 patients had favorable and 693 unfavorable prognoses. Patients in each prognostic group were randomized between standard and experimental treatment and first received two cycles of ABVD chemotherapy. Patients in the experimental arm who attained a negative early PET scan after the two cycles of ABVD chemotherapy were spared involved-node radiotherapy.

One progression occurred in the standard arm and nine progressions occurred in the research arm, for patients with a favorable prognosis and a negative early PET scan. For patients with unfavorable prognosis and a negative early PET scan, seven events occurred in the standard arm and 16 events occurred in the research arm. Even though there were few events and the median follow-up time short, the Independent Data Monitoring Committee concluded it was unlikely that the final results would show noninferiority for the experimental treatment. They, therefore, advised that randomization should be stopped for early PET-negative patients.
The study was closed for recruitment in June 2011 with a total of 1952 patients. The intergroup EORTC 20051 H10 trial is coordinated by the EORTC Lymphoma Group in collaboration with the LYmphoma Study Association (LYSA) and the Fondazione Italiana Linfomi (FIL). It is being conducted in 159 sites in eight countries: Belgium, Croatia, Denmark, France, Italy, Slovakia, Switzerland, and The Netherlands.

Related Links:

Radboud University Medical Center



Print article
Radcal

Channels

Radiography

view channel
Image: The CAD platform is available on the Aspire Cristalle digital mammography system (Photo courtesy of Fujifilm).

CAD Solution Available on New Digital Mammography System

An industry-leading provider of cancer detection, radiation therapy, and workflow solutions, has announced that the company's mammography CAD solution is now available on a new advanced Full Field Digital... Read more

General/Advanced Imaging

view channel

Early Intervention with Stent Retrievers Improves Outcomes for Ischemic Stroke Patients

New research has shown that restoration of blood flow to the brain within two and a half hours from the onset of the first signs of acute ischemic stroke resulted in none, or only minimal disability in 91% of patients. Endovascular therapy in the early stages of the onset of stroke symptoms significantly improved functional... Read more

Imaging IT

view channel

World Medical VR Technology Company Unveils First-of-Its-Kind Neurosurgery Surgical Visualization Platform

A novel neurosurgery Virtual Reality (VR) visualization platform has been demonstrated at the NVIDIA GPU Technology Conference (GTC) 2016 in California (USA). The enterprise-wide solution is intended to help clinicians plan, prepare, and perform neurosurgery, and enable the surgeon to empower and engage their patients... Read more

Industry News

view channel
Image: Mazor Robotics\' Renaissance Image Guidance Robot in the Hand of a Surgeon (Photo courtesy of Mazor Robotics).

Medical Image Guidance Systems Developer Reports Demand for Systems in Q1 2016

The developer of an innovative guidance system that can improve the accuracy and clinical outcomes for spine and brain surgery procedures, has announced demand for its systems during the first quarter of 2016.... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.